India
alveoair® has received U.S. FDA clearance, marking a significant advancement in respiratory care
alveofit® (Roundworks Technologies Private Limited) is thrilled to announce that its groundbreaking product, alveoair® spirometer, has earned U.S. FDA clearance for distribution in the United States. Specializing in digital therapeutics for respiratory care, the company is committed to delivering affordable and interoperable lung health solutions.
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence of HIV treatment for children in low- and middle-income countries
Aryastha Life Sciences Secures Series A funding from Vessella Group
Aryastha Life Sciences, a leading Contract Research and Development Organization in healthcare, has achieved a major milestone by successfully concluding its Series A funding with significant backing from Vessella Group, a prominent investor in India.
Japanese and Chinese Healthcare Companies Dominate in Asian Capital Market
A review of the top 25 Healthcare companies in Asia-Pacific
Sathgen Therapeutics completes dosing of the first two cohorts of healthy volunteers with MSP008-22, a novel anti-viral drug
Sathgen Therapeutics, a division of the leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), announced that they completed the dosing of the first two healthy volunteer cohorts in a Phase 1 clinical trial for MSP008-22, their new chemical entity (NCE).
Dr. Reddy’s Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent generic version of KOMBIGLYZE® XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food and Drug Administration (USFDA).
Game-changing Indian MRI Scanner Launched: Targets 6 billion People without Access to Cutting-edge Imaging Technologies
India-based company Voxelgrids has launched an advanced and affordable MRI scanner with the potential to revolutionize healthcare accessibility not only in India but also worldwide.
BPEA buys fertility clinic Indira IVF at valuation of $1.1 billion
Private equity firm BPEA EQT has acquired 60% of Indira IVF Hospital Pvt. Ltd, India’s largest chain of fertility clinics, from TA Associates and the fertility company’s founders at a valuation of about $1.1 billion, according to two people familiar with the transaction.
Dr. Reddy’s Q1 FY24 Financial Results
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2023.
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that its Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (USFDA).
